WebSite Logo
  • Content
  • Similar Resources
  • Metadata
  • Cite This
  • Language
    অসমীয়া বাংলা भोजपुरी डोगरी English ગુજરાતી हिंदी ಕನ್ನಡ
    Khasi कोंकणी मैथिली മലയാളം ꯃꯤꯇꯩ ꯂꯣꯟ मराठी Mizo नेपाली
    ଓଡ଼ିଆ ਪੰਜਾਬੀ संस्कृत ᱥᱟᱱᱛᱟᱲᱤ सिन्धी தமிழ் తెలుగు اردو
  • Log-in
  • Fullscreen
Log-in
Do not have an account? Register Now
Forgot your password? Account recovery
  1. Leukemia & lymphoma
  2. Year: 2010, Volume: 51
  3. Year: 2010, Volume: 51, Issue: 10
  4. Ribavirin as an anti-cancer therapy: Acute Myeloid Leukemia and beyond?
Loading...

Please wait, while we are loading the content...

Year: 2016, Volume: 57
Year: 2015, Volume: 56
Year: 2014, Volume: 55
Year: 2013, Volume: 54
Year: 2012, Volume: 53
Year: 2011, Volume: 52
Year: 2010, Volume: 51
Year: 2010, Volume: 51, Issue: 12
Year: 2010, Volume: 51, Issue: 10
Ribavirin as an anti-cancer therapy: Acute Myeloid Leukemia and beyond?
Year: 2010, Volume: 51, Issue: 9
Year: 2010, Volume: 51, Issue: 8
Year: 2010, Volume: 51, Issue: 7
Year: 2010, Volume: 51, Issue: 6
Year: 2010, Volume: 51, Issue: 5
Year: 2010, Volume: 51, Issue: 4
Year: 2010, Volume: 51, Issue: 3
Year: 2010, Volume: 51, Issue: 2
Year: 2010, Volume: 51, Issue: 1
Year: 2009, Volume: 50
Year: 2008, Volume: 49
Year: 2006, Volume: 47
Year: 2004, Volume: 45
Year: 2003, Volume: 44

Similar Documents

...
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies

Review

...
The frequency of NPM1 mutations in childhood acute myeloid leukemia

Article

...
Precision therapy for acute myeloid leukemia

Review

...
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia

...
Recent advances in targeted therapies in acute myeloid leukemia

Review

...
CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation

Article

...
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

Review

...
Targeting CLL-1 for acute myeloid leukemia therapy

Review

...
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis

Article

Ribavirin as an anti-cancer therapy: Acute Myeloid Leukemia and beyond?

Content Provider PubMed Central
Author Borden, Katherine L. B. Culjkovic-kraljacic, Biljana
Abstract Ribavirin was discovered nearly 40 years as a broad-spectrum anti-viral drug. Recent data suggest that ribavirin may also be an effective cancer therapy. In this case, ribavirin targets an oncogene, the eukaryotic translation initiation factor eIF4E, elevated in approximately 30% of cancers including many leukemias and lymphomas. Specifically, ribavirin impedes eIF4E mediated oncogenic transformation by acting as an inhibitor of eIF4E. In a Phase II clinical trial, ribavirin treatment led to substantial clinical benefit in poor prognosis acute myeloid leukemia (AML) patients. Here molecular targeting of eIF4E correlated with clinical response. Ribavirin also targets a key enzyme in the guanosine biosynthetic pathway, inosine monophosphate dehydrogenase (IMPDH), and also, modulates immunity. Parallels with known anti-viral mechanisms could be informative; however after 40 years, these are not entirely clear. The anti-viral effects of ribavirin appear cell type specific. This variation likely arises for many reasons including cell specific variations in ribavirin metabolism as well as virus specific factors. Thus, it seems that the mechanisms for ribavirin action in cancer therapy may also vary in terms of the cancer/tissue under study. Here we review the anticancer activities of ribavirin and discuss the possible utility of incorporating ribavirin into diverse cancer therapeutic regimens.
Related Links http://dx.doi.org/10.3109/10428194.2010.496506
Ending Page 1815
Page Count 11
Starting Page 1805
File Format PDF
ISSN 10428194
e-ISSN 10292403
Journal Leukemia & lymphoma
Issue Number 10
Volume Number 51
Language English
Publisher Date 2010-10-01
Access Restriction Open
Subject Keyword Cancer Research Oncology Hematology Research in Higher Education
Content Type Text
Resource Type Article
Subject Hematology Cancer Research Oncology
  • About
  • Disclaimer
  • Feedback
  • Sponsor
  • Contact
About National Digital Library of India (NDLI)
NDLI logo

National Digital Library of India (NDLI) is a virtual repository of learning resources which is not just a repository with search/browse facilities but provides a host of services for the learner community. It is sponsored and mentored by Ministry of Education, Government of India, through its National Mission on Education through Information and Communication Technology (NMEICT). Filtered and federated searching is employed to facilitate focused searching so that learners can find the right resource with least effort and in minimum time. NDLI provides user group-specific services such as Examination Preparatory for School and College students and job aspirants. Services for Researchers and general learners are also provided. NDLI is designed to hold content of any language and provides interface support for 10 most widely used Indian languages. It is built to provide support for all academic levels including researchers and life-long learners, all disciplines, all popular forms of access devices and differently-abled learners. It is designed to enable people to learn and prepare from best practices from all over the world and to facilitate researchers to perform inter-linked exploration from multiple sources. It is developed, operated and maintained from Indian Institute of Technology Kharagpur.

Learn more about this project from here.

Disclaimer

NDLI is a conglomeration of freely available or institutionally contributed or donated or publisher managed contents. Almost all these contents are hosted and accessed from respective sources. The responsibility for authenticity, relevance, completeness, accuracy, reliability and suitability of these contents rests with the respective organization and NDLI has no responsibility or liability for these. Every effort is made to keep the NDLI portal up and running smoothly unless there are some unavoidable technical issues.

Feedback

Sponsor

Ministry of Education, through its National Mission on Education through Information and Communication Technology (NMEICT), has sponsored and funded the National Digital Library of India (NDLI) project.

Contact National Digital Library of India
Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302
See location in the Map
03222 282435
Mail: support@ndl.gov.in
Sl. Authority Responsibilities Communication Details
1 Ministry of Education (GoI),
Department of Higher Education
Sanctioning Authority https://www.education.gov.in/ict-initiatives
2 Indian Institute of Technology Kharagpur Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project https://www.iitkgp.ac.in
3 National Digital Library of India Office, Indian Institute of Technology Kharagpur The administrative and infrastructural headquarters of the project Dr. B. Sutradhar  bsutra@ndl.gov.in
4 Project PI / Joint PI Principal Investigator and Joint Principal Investigators of the project Dr. B. Sutradhar  bsutra@ndl.gov.in
Prof. Saswat Chakrabarti  will be added soon
5 Website/Portal (Helpdesk) Queries regarding NDLI and its services support@ndl.gov.in
6 Contents and Copyright Issues Queries related to content curation and copyright issues content@ndl.gov.in
7 National Digital Library of India Club (NDLI Club) Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach clubsupport@ndl.gov.in
8 Digital Preservation Centre (DPC) Assistance with digitizing and archiving copyright-free printed books dpc@ndl.gov.in
9 IDR Setup or Support Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops idr@ndl.gov.in
Cite this Content
Loading...